Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MAIA Biotechnology Inc. (MAIA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: MAIA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12.13
1 Year Target Price $12.13
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.05% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 51.47M USD | Price to earnings Ratio - | 1Y Target Price 12.13 |
Price to earnings Ratio - | 1Y Target Price 12.13 | ||
Volume (30-day avg) 1 | Beta 0.03 | 52 Weeks Range 1.40 - 3.74 | Updated Date 08/15/2025 |
52 Weeks Range 1.40 - 3.74 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.54 |
Earnings Date
Report Date 2025-08-05 | When - | Estimate -0.25 | Actual -0.1679 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -107.22% | Return on Equity (TTM) -459.53% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 41324901 | Price to Sales(TTM) - |
Enterprise Value 41324901 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.34 | Shares Outstanding 32993200 | Shares Floating 28339856 |
Shares Outstanding 32993200 | Shares Floating 28339856 | ||
Percent Insiders 21.43 | Percent Institutions 6.92 |
Upturn AI SWOT
MAIA Biotechnology Inc.
Company Overview
History and Background
MAIA Biotechnology, Inc. is a biopharmaceutical company focused on developing targeted cancer therapies. It was founded in 2016 and is based in Chicago, Illinois. The company is dedicated to developing innovative drugs that target telomere biology in cancer cells.
Core Business Areas
- Drug Development: MAIA focuses on developing clinical-stage therapies, including THIO, which is a telomere-targeting agent designed to selectively target and destroy cancer cells.
Leadership and Structure
Vlad Vitoc is the Chairman, President, and CEO of MAIA Biotechnology. The company has a board of directors and a management team overseeing clinical development and business operations.
Top Products and Market Share
Key Offerings
- THIO (Telomere-Targeting Agent): THIO is MAIA's lead drug candidate. It's a telomere-targeting agent being developed for various cancers. Current trials are in phase 2. Market share data specific to THIO is unavailable, as it is still in clinical development and faces competition from standard chemotherapy, radiation, and other targeted therapies like those offered by Bristol Myers Squibb, Merck and Roche.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high research and development costs, and stringent regulatory requirements. Targeted cancer therapies are a growing segment, driven by the need for more effective and less toxic treatments.
Positioning
MAIA Biotechnology is positioned as a clinical-stage company focused on innovative cancer therapies targeting telomeres. Its competitive advantage lies in its specific approach to cancer treatment and intellectual property surrounding THIO.
Total Addressable Market (TAM)
The global oncology market is estimated to reach hundreds of billions of dollars. MAIA's potential market share depends on the clinical success of THIO and its ability to penetrate specific cancer segments. Specific projections are highly dependent on trial outcomes.
Upturn SWOT Analysis
Strengths
- Novel telomere-targeting technology
- Clinical-stage asset (THIO)
- Experienced management team
Weaknesses
- Limited financial resources
- Reliance on a single key asset (THIO)
- High risk associated with clinical development
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
Threats
- Clinical trial failures
- Competition from established therapies
- Regulatory hurdles
- Patent disputes
Competitors and Market Share
Key Competitors
- BMY
- MRK
- RHHBY
Competitive Landscape
MAIA faces intense competition from established pharmaceutical companies with broader portfolios and greater resources. Its advantage lies in its novel approach, but it faces significant risks in clinical development.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical and clinical development progress rather than revenue generation.
Future Projections: Future growth depends on the successful development and commercialization of THIO. Analyst estimates vary widely based on clinical trial outcomes and market adoption.
Recent Initiatives: Recent initiatives include progressing THIO through clinical trials and exploring partnerships for further development and commercialization.
Summary
MAIA Biotechnology is a development-stage company focused on a novel cancer therapy. Its strength lies in its unique telomere-targeting technology and ongoing clinical trials. However, it faces financial constraints and significant clinical development risks. Success hinges on the outcome of THIO's clinical trials and potential partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MAIA Biotechnology Inc.
Exchange NYSE MKT | Headquaters Chicago, IL, United States | ||
IPO Launch date 2022-07-28 | Co-Founder, President, CEO & Chairman of the Board of Directors Dr. Vlad Vitoc M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://maiabiotech.com |
Full time employees 13 | Website https://maiabiotech.com | ||
MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.